What is Evommune 's working capital?

Evommune (EVMN) reported working capital of -$559.48K in Q1 2026.

What does working capital mean?

Working capital represents the difference between a company's current assets and current liabilities. It serves as a primary indicator of a firm's short-term liquidity and its ability to fund ongoing clinical development programs and operational expenses. A positive balance indicates sufficient liquid resources to meet immediate financial obligations.

Evommune EVMN Working Capital

Working Capital at other companies

Quantum Computing Inc.QUBT

$990M—

Twenty One Capital XXI

$117.85M—

Nano Nuclear EnergyNNE

$565.73M+392%

JAN

Janus Living JAN

-$5.5M—

Nurix Therapeutics, Inc.NRIX

$520.3M—

Polaryx Therapeutics, Inc. PLYX

$2.5M—

Other financials

Income statement

See full

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

See full

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

See full

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

See full

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

See full

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

See full

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept meha:WorkingCapital.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Evommune 's working capital?: Evommune (EVMN) reported working capital of -$559.48K in Q1 2026.
What does working capital mean?: Working capital represents the difference between a company's current assets and current liabilities. It serves as a primary indicator of a firm's short-term liquidity and its ability to fund ongoing clinical development programs and operational expenses. A positive balance indicates sufficient liquid resources to meet immediate financial obligations.